Photobiomodulation therapy in nonalcoholic fatty liverdisease

Introduction: Photobiomodulation Therapy (PBMT) can be safely employed in the treatment of liver diseases, such as Non-Alcoholic Fatty Liver Disease (NAFLD). Materials and Methods: 32 individuals with a mean age range between 51.03 ± 9.58 years, suffering from NAFLD diagnosed by ultrasonography, were randomized into 2 study groups: Placebo's Group and PBMT's Group. Before and after the analysis period given to each group, the aforementioned individuals underwent liver ultrasonography aswell as BMI calculation and their blood samples were submitted to the following laboratory tests (plasma concentrations): Alanine Transaminase (ALT), Aspartate Transaminase (AST), Alkaline Phosphatase (ALP), Bilirubin (total and fractions) (BILI), Gamma-Glutamyl Transpeptidase or Gamma-GT (GGT), Prothrombin Time Activity (PT or PTA), Total Cholesterol and Fractions (TC - HDL, LDL) and Triglycerides (TG). Results: The PBMT’s Group demonstrated improvement in steatosis status in 93.8% of patients whereas the Placebo’s Group showed improvement in the percentage of 37.5%. Reductions in Triglycerides, Total Cholesterol, LDLand GGT levels were also observed in the PBMT’s Group. Discussion: There was a significant enhancement in steatosis grade in the group that underwent treatment with PBMT, indicating it as a safe and effective method for treating patients with NAFLD.